My watch list  


Levormeloxifene is a selective estrogen receptor modulator that was developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials.


  • Ravn P, Nielsen TF, Christiansen C. (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135-42. PMID 16532904.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Levormeloxifene". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE